Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark
- CCBR A/S
-
Ballerup, Denmark
- CCBR A/S
-
Copenhagen NV, Denmark
- Y Forskning, Bispebjerg Hospital
-
Frederiksberg, Denmark
- Frederiks Hospital, Kardiologisk
-
Hellerup, Denmark
- Kolesterollaboratoriet
-
Vejle, Denmark
- CCBR A/S
-
-
-
-
-
Breda, Netherlands
- Middellaan 5
-
Eindhoven, Netherlands
- Bomanshof 8
-
Groningen, Netherlands
- Damsterdiep 9
-
Leiden, Netherlands
- Doezastraat 1
-
Nijmegen, Netherlands
- Kamerlingh Onnesstraat 16-18
-
Rotterdam, Netherlands
- Mathenesserlaan 247
-
Velp, Netherlands
- Reigerstraat 30
-
Zoetermeer, Netherlands
- Parkdreef 142
-
-
-
-
-
Barcelona, Spain
- Hospital Universitario de Bellvitge
-
Barcelona, Spain
- Hospital Vall d'hebrón
-
Cordoba, Spain
- Hospital Universitario Reina Sofia
-
Madrid, Spain
- Hospital Ramon y Cajal
-
Madrid, Spain
- Fundación Jiménez Díaz
-
Madrid, Spain
- Hospital Clinico San Carlos
-
Santiago de Compostela, Spain
- Hospital Clínico Universitario de Santiago
-
Valencia, Spain
- Hospital de Sagunto
-
-
Alicante
-
San Juan, Alicante, Spain
- Hospital Clinico S. Juan de Alicante
-
-
Barcelona
-
Villaroel, Barcelona, Spain
- Hospital Clinic I Provincial
-
-
-
-
-
Angelhom, Sweden
- Angelholms Sjukhus, Medicinkliniken
-
Gothenburg, Sweden
- Sahlgrenska University Hospital, Intermedicin
-
Helsingborg, Sweden
- Hjärtmottagningen
-
Karineholm, Sweden
- Lakarcentrum Nyponet
-
Ludvika, Sweden
- Medicinkliniken
-
Malmo, Sweden
- Hjärtmottagningen
-
Sandviken, Sweden
- Huslakaren i Sandviken
-
Sandviken, Sweden
- Narsjukhuset Sandviken, Kardiologlab, Medicin
-
Sodertalje, Sweden
- Hjart & Karlcenter
-
Stockholm, Sweden
- Karolinska Universitetssjukhuset
-
Varberg, Sweden
- Hjarthuset AB
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females (18-75 years of age)
- At least two cardiovascular disease risk factors
- Must have been following a restrictive diet
- Diagnosis of primary hypercholesterolemia or combined dyslipidemia
Exclusion Criteria:
- Homozygous familial hypercholesterolemia
- Conditions which may cause secondary dyslipidemia
- Uncontrolled diabetes mellitus
- Abnormal pancreatic, liver or renal function
- Abnormal serum creatine kinase (CK) above the pre-specified level
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pitavastatin 4 mg QD
Pitavastatin 4 mg once daily
|
|
|
Active Comparator: Simvastatin 40 mg QD
Simvastatin 40 mg once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in LDL-C
Time Frame: 12 weeks
|
Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients Attaining NCEP LDL-C Target (< 160 mg/dL)
Time Frame: 12 weeks
|
Number of patients attaining LDL-C target according to National Cholesterol Education Program (NCEP) criteria (< 160 mg/dL)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Dragos Budinski, Med Dr., Medical Director
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
- Pitavastatin
Other Study ID Numbers
Other Study ID Numbers
- NK-104-304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.